drugset / Trial / NCT05782972
Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study
Phase 4
Active not recruiting
50 enrolled
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
NaSingle-groupOpen-labelTreatment
Summary
The goal of this single arm, prospective study is to test the therapeutic response of oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks in non-diabetic MAFLD patients. The primary outcomes are the improvement of liver inflammation or fibrosis parameters after 24 weeks treatment. The adverse events were also recorded.
Timeline
- Start
- 2023-03-11
- Primary completion
- 2025-11-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | Oral |